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summAry – The role of T regulatory lymphocytes (Treg) particularly in cancer is well known. 
The goal of the present study was to determine the contribution of these lymphocytes in the regulation 
of anti-tumor immunity of CbA/hZgr mice against mC-2 fibrosarcoma (4th generation of methyl-
cholanthrene induced tumor). The levels of T lymphocytes (CD4+, CD8+ and CD4+CD25+) were 
determined 8 and 20 days after tumor transplantation. further, the role of CD4+CD25+ (Tregs) in 
tumor-host interaction was evaluated in vitro and in vivo by using specific monoclonal antibodies.  
We found that splenocytes of both control and Treg depleted tumor bearing mice strongly but differ-
ently inhibited growth of tumor cells in vitro. While splenocytes of untreated mice exhibited signifi-
cant decrease of this activity (from 74.4% to 62.6% and 32.95%), the splenocytes of Treg depleted  
mice showed increase of this activity (from 79.5% to 84.3% and 86.2%) from day 6 to day 13 and  
day 21 after tumor grafting, respectively. further, upon i.v. injecting specific monoclonal anti-Treg  
antibody tumor immediately prior to tumor cell intracutaneous transplantation, the tumor was  rejected 
after initial growth. in treated mice, the incidence of Treg cells was very low initially, reaching normal 
values two weeks later. These animals were shown to be resistant to tumor transplantation four months 
later.
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Introduction
immune homeostasis is maintained by regulatory 
T cells (Treg) which actively suppress immune response 
and protect the host against autoimmune diseases1-4. 
These cells have been described as CD4+CD25+, 
characterized by the expression of il2 receptor (CD25 
molecule) and the costimulatory molecule CD45. Tregs, 
acting as immune suppres sion for body tissues, have 
been demonstrated to play an essential role in self-
tolerance, transplantation, allergy and tumor/microbial 
immunity6. indeed, accumulating evidence implicates 
Tregs as one of the principal cell types suppressing 
TAA-specific lymphocyte activity and tumor eradica-
tion, and thus one of the major obstacles to effective 
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anti-tumor immunotherapy7-10. CD25+CD4+ regu-
latory T cells (Treg) comprise 5%-10% of the circu-
lating CD4+ T cell population and suppress tumor 
immune responses11. indirect evidence sug gests that 
CD4+CD25+ T cells (Tregs) are important in suppress-
ing TAA-specific immunity12,13,, and they suppress 
nonspecific T cell responses in vitro. it is critical that 
the mechanism that contrib utes to Treg accumulation 
in tumors is not fully understood. it has been suggest-
ed that Tregs display an enhanced capacity for infiltra-
tion of, and accumulation within the tumor in compari-
son to effector T cells7.
it was shown that Treg cells were activated through 
their T-cell receptors in antigen-specific manner but 
they can inhibit effector cells in an antigen-unspecific 
way6-8. further, human and murine Treg cells were 
shown to secrete immunosuppressive cytokines9-11. Treg 
cells could have beneficial effects in the body by pre-
venting autoimmune diseases but, on the other hand, 
they act against the body by suppressing host’s im-
mune reaction against tumor1,12,13. CD25+ is overex-
pressed in certain lymphoid malignancies, on activated 
T cells involved in autoimmune disorders, and in al-
lograft rejection. increased CD25+ expression has 
been demonstrated in anaplastic large-cell lymphoma, 
adult T-cell leukemia (ATl)/lymphoma, chronic lym-
phocytic leukemia, cutaneous T-cell lymphoma, hairy 
cell leukemia, some b-cell non-hodgkin’s lymphomas, 
and hodgkin’s lymphoma14.
several reports have pointed to pronounced deple-
tion of Treg cells after application of specific monoclo-
nal antibodies in several mouse tumor models, result-
ing in slow tumor growth and prolonged survival of 
treated animals15,16. The immune system in higher ver-
tebrates protects the body against a wide and change-
able spectrum of pathogenic organisms or antigens, 
while complex mechanisms in the thymus and periph-
eral lymphoid organs prevent reaction to the host’s 
own (self ) antigens1-4,17. suppressor activity of regula-
tory T lymphocytes characterized as CD4+CD25+ is 
necessary for this tolerance of self antigens4,18. An im-
portant mechanism involves the action of regulatory T 
cells to maintain immune balance of the organism to 
be tolerant to self, while remaining competent to 
mount an effective immune response against third 
party antigens3,4. The activities of the immune system 
play an important role in the relations between a host 
and its tumor. numerous clinical and experimental 
data point to a specific immune reaction against a 
growing tumor and it is likely that these immune re-
sponses develop in much the same way as they do to 
pathogens or foreign antigens3,12. Thus, anti-tumor an-
tibodies and T cells are generated and, along with non-
specific immune mechanisms, play a role in tumor im-
munity. further, it should be mentioned that a growing 
tumor, by releasing particular cytokines, may be im-
munosuppressive and may stimulate production of 
regulatory T lymphocytes19-21.
The anti-CD25 monoclonal antibody is one of the 
most used treatments for steroid-refractory graft-ver-
sus-host disease (gVhD) and could selectively inhibit 
activated T cells, and therefore does not increase the 
risk of relapse of leukemia. The study by Tao et al. 
showed that CD25+ lymphocyte proportion signifi-
cantly decreased after anti-CD25 monoclonal anti-
body treatment, suggesting that CD25+ lymphocytes 
were strongly inhibited22.
We performed in vitro and in vivo experiments by 
using specific anti-CD25 monoclonal antibody in our 
well defined mouse tumor model, CbA/hZgr mice 
and mC-2 transplanted fibrosarcoma (4th generation 
of methylcholanthrene induced tumor) with known 
dynamics of T cells in tumorous mice. Actually, lym-
phoid cells from tumor bearing mice were in a classical 
colony inhibition test treated with specific anti-CD25 
monoclonal antibody and cultivated with tumor cells. 
for in vivo studies, the mice with transplanted tumor 
were treated with specific anti-CD25 monoclonal an-
tibody. The incidence of particular T cell populations, 




male mice of CbA/hZgr strain were obtained 
from Animal breading unit of ruđer bošković insti-
tute (Zagreb, Croatia). At the beginning of the experi-
ment, the animals were about three months old with 
body weight 20-22 g. They were kept in plastic cages of 
five mice each. Admission to food (4 rf 21 gPl 
mucedola srl, italy) and tap water was ad libitum. The 
temperature of the room with experimental animals 
was 22o C, humidity 55% and light-dark intervals ex-
changed every 12 hours. All experiments were per-
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formed in accordance with the Croatian act on animal 
welfare.
Tumor
fibrosarcoma mC-2 was used in the experiments. 
The tumor was induced by injecting methylcholan-
threne dissolved in olive oil subcutaneously into CbA/
hZgr female mouse. We have several generations of 
the tumor in our tumor bank. The tumor of the 4th 
generation was used in all experiments.
Tumor cell suspension was mechanically prepared 
from growing tumor as described previously23, with 107 
viable cells in 1 ml. The mice were injected subcutane-
ously with 0.1 ml of the suspension (106 viable cells) 
and, in the experiments with monoclonal antibody, 105 
cells were injected intracutaneously. by using the cali-
per (Cambridge, usA), three orthogonal diameters 
(A, b and C) of growing tumor were determined every 
three days. Tumor volume was determined by using 
the AbCπ/6 formula.
for in vitro experiments, tumor cell suspension was 
cultivated in rPmi media (institute of immunology, 
Zagreb, Croatia) supplemented with 10% of fetal calf 
serum (fCs) (sigma, usA). The cell cultures were 
kept in the incubator (heraeus, germany) at 37 oC in 
humid atmosphere with 5% of Co2.
Lymphocyte spleen cell suspension
on particular days after tumor transplantation, the 
mice were sacrificed, spleens removed, single cell sus-
pension prepared mechanically and lymphocytes were 
isolated on a density gradient by using lymphoprep24.
Determination of lymphocyte populations
spleen lymphocytes were washed once in phos-
phate buffered saline (Pbs) ph 7.3 with 5% fCs ad-
justed to final concentration of 1x106 cell/ml and in-
cubated with particular monoclonal antibodies for 30 
minutes on ice in dark. monoclonal antibodies anti-
CD3, anti-CD4, anti-CD8 and anti-CD25, as phyco-
erithrin or fiTC conjugate (bD Pharmingen biosci-
ence, usA) and corresponding isotype controls were 
used. The cells were washed in Pbs, centrifuged at 
200xg for 5 minutes and resuspended in Pbs with 5% 
fCs. All samples were finally resuspended in a prop-
idium iodide (1 μg/ml) containing buffer.
Flow cytometric analysis
The fluorescence intensity at the single cell level 
was evaluated by flow cytometry (fACscalibur, bec-
ton Dickinson, mountain View, usA). for each sam-
ple, 10,000 cells were analyzed. fluorescence signals 
were recorded on a frequency histogram or dot plot 
using logarithmic amplification. Cells were considered 
unstained if the associated fluorescence did not differ 
from the fluorescence of cells labeled with isotype con-
trol (negative control). nonviable cells labeled with 
propidium iodide were excluded from analysis.
Cultivation of tumor cells with lymphocytes
microplates with 96 wells (greiner, germany) 
were used. Tumor cell suspension from the culture was 
prepared to contain 8x103 viable cells in 1 ml, 0.1 ml 
poured in each well complemented with 5x105 lym-
phocytes, and tumor cell number was determined by 
using an inverse microscope (Zeiss, germany) three 
days later, as described previuously17.
specific monoclonal antibody 7D4 (bD Phar-
mingen bioscience, usA) was used to eliminate 
CD4+CD25+ cells from lymphocyte suspension. 
briefly, 106 lymphocytes were incubated with 1 μg of 
7D4 antibody at 4 oC during 1 hour, followed by cen-
trifugation (150xg) for 10 minutes, resuspended in the 
medium and cultivated at 37 oC for an additional hour. 
Double washing with the medium (150xg for 5 min-
utes) was performed and, in the presence of monoclo-
nal antibody hybridoma PC61 (which does not com-
pete with 7D4 antibody), it was confirmed that there 
was less than 0.1% of lymphocytes with CD25 anti-
gen.
Monoclonal antibody application  
in tumor transplanted mice
The anti-CD25 monoclonal antibody (clone PC61, 
rat anti mouse; Pharmingen biosciences, usA) was 
injected (0.25 mg in 0.2 ml of the hanks solution) 
intravenously (i.v.) in the mice immediately prior to 
intracutaneous injection of 105 viable tumor cells. 
Control animals were injected with rat immunoglobu-
lins of the same manufacturer.
Statistical analysis
mean values and standard deviations were deter-
mined for each of the experimental groups. significanc-
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es were determined by using AnoVA and Tukey post-
hoc test. statistical significance was defined as p<0.05.
Results
Dynamics of T lymphocyte populations  
during tumor growth
The CbA/hZgr mice were transplanted with mC-2 
fibrosarcoma cells. eight or 20 days later, the animals 
with growing tumor were sacrificed, spleen cell suspen-
sions prepared, lymphocytes isolated and the incidence 
of CD4+, CD8+, as well as CD4+CD25+ T cells deter-
mined by using specific monoclonal antibodies. There 
were seven mice in each group of tumor-transplanted 
mice and seven control mice without tumor.
The results are presented in figure 1. As shown, the 
incidence of CD4+ and CD8+ cells decreased whereas 
the CD4+CD25+ incidence increased during tumor 
growth. Differences between control and tumor bear-
ing mice were significant (p<0.01).
besides, about 10% of all CD4+ cell populations 
were CD4+CD25+ cells, which is consistent with the 
data already known.
The influence of specific anti-CD25 monoclonal 
antibodies against the tumor determined in vitro  
and in vivo
for in vitro experiments, lymphocytes were isolated 
from the spleen of CbA/hZgr mice transplanted with 
mC-2 fibrosarcoma cells and sacrificed 2, 6, 13 and 21 
days later. Tumor cells were cultivated with the lympho-
cytes isolated from tumor bearing and from normal 
mice. furthermore, the 7D4 monoclonal antibody was 
used to remove CD25+ cells from lymphocyte popula-
tion. As presented in Table 1, the lymphocytes from tu-
mor bearing mice were effective in destroying tumor 
cells, but the bigger the tumor, the less effective the lym-
phocytes were (74.4%, 62.6% and 32.1% of control val-
ues). however, the elimination of CD25+ cells resulted 
in well pronounced anti-tumor activity of lymphocytes 
isolated from tumor bearing mice regardless of tumor 
size (79.5% to 86.2% of control values).
for in vivo experiments, the anti-CD25 (clone 
PC61) monoclonal antibody (rat anti mouse) was in-
jected i.v. into CbA/hZgr mice transplanted intracu-
taneously with mC-2 fibrosarcoma cells immediately 
Fig. 1. Incidence of CD4+, CD8+ and CD4+CD25+ 
lymphocytes in the spleen of CBA/HZgr mice 
transplanted with fibrosarcoma MC-2, determined on 
particular days during tumor growth. Small letters above 
bars indicate significant differences among the groups 
(p<0.01).
Table 1. Fibrosarcoma MC-2 cell count determined 3 days after cultivation with lymphocytes from normal or tumor 
bearing mice, cultivated in microplates. Lymphocytes from tumor bearing mice were collected on particular days  


















lymphocytes from tumor bearing 
mice (CD25+ eliminated)
2 0.0 103.2±3.3 104.0±3.1 102.9±2.9 103.2±3.3
6 8.4 99.7±2.0 100.1±2.9 25.6±2.1 20.5±2.1
13 326.4 89.1±2.0 87.8±3.1 32.8±3.1 13.8±2.4
21 2216.8 102.6±3.0 103.6±2.6 69.8±2.4 14.3±2.9
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after antibody application. Tumor control mice were 
injected with normal rat serum. As shown in figure 2, 
initial tumor growth occurred in both groups, i.e. in 
five mice from each group. however, after day 6, tumor 
regression was noticed in the specific monoclonal an-
tibody treated group, whereas in the control group it 
was growing. injection of specific monoclonal anti-
body at different times with regard to tumor applica-
tion was not successful (data not shown).
The mice that rejected the tumor following anti-
CD25 monoclonal antibody treatment were trans-
planted with 106 viable tumor cells four months later. 
however, the tumor did not develop. furthermore, as 
illustrated in figure 3, the incidence of CD4+CD25+ 
lymphocytes was very low in monoclonal antibody 
treated mice in comparison to the results shown in 
figure 1, while the incidences of CD4+ and CD8+ 
cells were normal throughout the observation period. 
it should be noted that the incidence of CD4+CD25+ 
lymphocytes in these mice determined 14 days after 
tumor transplantation reached the values observed in 
control mice (see fig. 1).
Discussion
The CD25+ lymphocytes with their il-2 receptor 
are a critical non-redundant regulator of immune ho-
meostasis. There is increasing interest in the therapeu-
tic role of il-2 signalization to promote immune acti-
vation in tumor immunotherapy or enhance immune 
suppression in transplantations, autoimmunity and 
inflammatory diseases25.
Adoptive cell therapy is an emerging treatment 
strategy for a number of serious diseases. regulatory T 
(Treg) cells are a cell type of particular interest for ther-
apy of inflammatory conditions, as they are responsible 
for controlling unwanted immune responses. The goal 
of our study was to evaluate the role of CD4+CD25+ 
Treg lymphocytes (in vitro and in vivo) by using spe-
cific anti-CD25 monoclonal antibody in a mouse tu-
mor model.
The results presented in this paper indicate that in 
our experimental model the incidence of anti-tumor 
lymphocytes, CD4+ and CD8+, decreased while sup-
pressor CD4+CD25+ lymphocytes increased in the 
spleen of tumor-transplanted mice during tumor 
growth. This is consistent with the already published 
results26-28. lymphocytes from tumor bearing mice are 
cytotoxic against tumor cells in vitro, which is in ac-
cordance with our previous and other results29-32. As 
presented, lymphocyte anti-tumor activity decreased 
with tumor growth and previous results indicate that 
this activity recovered after tumor elimination31-33. 
Fig. 2. Tumor growth curves after fibrosarcoma MC-2 
cell intracutaneous injection to CBA/HZgr mice. The mice 
were intravenously injected either with monoclonal anti-
CD25 antibody (rat anti mouse) or with normal rat 
immunoglobulins immediately prior to tumor 
transplantation. There were five mice per group.
Fig. 3. Incidence of CD4+, CD8+ and CD4+CD25+ 
lymphocytes on particular days in the spleen of CBA/
HZgr mice transplanted intracutaneously with 
fibrosarcoma MC-2 cells and intravenously with 
monoclonal anti-CD25 antibody (rat anti mouse) 
immediately prior to tumor transplantation. Small letters 
above bars indicate significant differences among the 
groups (p<0.01).
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furthermore, as presented in this paper, specific mono-
clonal antibody recovered anti-tumor reactivity of T 
lymphocytes by eliminating CD25+ lymphocytes. 
similar results on the role of suppressor lymphocytes 
in tumor-host relation have been published16,34,35, 
pointing to detrimental situation in patients if these 
cells infiltrate their tumor34,36. son et al.37 investigated 
the potential of anti-CD25 monoclonal antibody to 
prevent activation of Treg lymphocytes during radiation 
therapy. Anti-CD25 monoclonal antibody inhibited 
Treg lymphocytes and improved the therapeutic effect 
of irradiation in a mouse model of lung and colon can-
cer. Combined treatment of anti-CD25 monoclonal 
antibody with radiation significantly decreased Treg in 
the spleen and tumor compared with control and ir-
radiation only in both lung and colon cancer. Combi-
natorial treatments resulted in a significant increase in 
the effector T cells, longer survival rate, and suppressed 
irradiated and distal non-irradiated tumor growth37.
moreover, the presented results of our study simi-
larly indicate that the application of specific anti 
CD25+ antibody to tumor transplanted mice at spe-
cific time resulted in normal incidence of CD4+ and 
CD8+ cells throughout the observation period while 
the CD4+CD25+ incidence was extremely low during 
the initial period after antibody and tumor injection. 
After initial growth, the tumor was rejected and, which 
is particularly interesting, these mice were resistant to 
subsequent tumor transplantation. it could be con-
cluded that these animals became resistant to tumor by 
stimulation of the effector T cells during tumor growth 
and that a lower incidence of CD4+CD25+ cells re-
sulted in tumor elimination. memory cells responsible 
for antitumor resistance probably developed during 
transplanted tumor growth and the tumor was elimi-
nated after specific monoclonal anti-CD25+ antibody 
application at a proper time.
The studies on the role of lymphocytes are funda-
mental in understanding immune mechanisms in tu-
mor disease. however, the double role of CD4+ T 
lymphocytes has important clinical implications as 
CD4 T helper cells keep CD8+ memory cells while 
CD4+CD25+ cells are important in anti-tumor re-
sponse inhibition38-41. These opposite effects of CD4+ 
T lymphocytes call for further investigations on their 
role in possible clinical approaches. results suggest 
that Treg depletion strategies may enhance antitumor 
immunity and additionally improve disease outcomes.
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sažetak
ulogA regulATornih T limfoCiTA  
u imunosnoJ KonTroli mC-2 fibrosArKomA
T. Jukić, A. Jurin Martić, S. Ivanković, M. Antica, D. Pavan Jukić, C. Rotim i M. Jurin
uloga T regulatornih limfocita dobro je poznata, osobito kod tumora. Cilj ovoga istraživanja bio je utvrditi doprinos ovih 
limfocita u regulaciji antitumorske imunosti CbA/hZgr miševa protiv mC-2 fibrosarkoma (4. generacija metilkolantrenom 
izazvanog tumora). razine T limfocita (CD4+, CD8+ and CD4+CD25+) određivale su se 8 i 20 dana nakon transplantacije 
tumora. nadalje, uloga CD4+CD25+ T limfocita (Treg) u interakciji tumora i domaćina procijenjena je in vitro i in vivo 
 primjenom specifičnih monoklonskih protutijela. utvrdili smo da splenociti kako kontrolnih miševa tako i miševa s tumorom 
bez Treg snažno, ali različito suzbijaju rast tumorskih stanica in vitro. Dok su splenociti netretiranih miševa pokazivali zna-
čajno smanjenje ove aktivnosti (sa 74,4% na 62,6% i 32,95%), splenociti miševa bez Treg pokazivali su porast ove aktivnosti 
(sa 79,5% na 84,3% i 86,2%) od 6. do 13. i 21. dana nakon transplantacije tumora. uz to, nakon i.v. injektiranja specifičnog 
monoklonskog anti-Treg tumorskog protutijela neposredno prije intrakutane transplantacije tumorskih stanica, nakon po-
četkog rasta nastupilo je odbacivanje tumora. Kod tretiranih miševa incidencija Treg stanica bila u početku vrlo niska i dostigla 
je normalne vrijednosti dva tjedna kasnije. nakon četiri mjeseca pokazalo se da su ove životinje otporne na transplantaciju 
tumora.
Ključne riječi: Regulatorni T limfociti; Tumorski rast; Specifična monoklonska protutijela; Eksperimentalni miševi
